2018.Sep.03

OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities

1.Date of the event: Sep 5, 2018 2.Time: 14:30:00 CST 3.Location：Masterlink Securities (Address: No.97-11, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, Taiwan) 4.Summary: OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities 5.Any other matters that need to be specified: None Please refer to MOPS for stop-acne-meds.com financial information […]

HOMEWhat’s NewAnnouncementsOBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2018.Aug.15

OBI received notice from patent attorney’s office that product patent for OBI-3424 named "DNA alkylating agents" has been approved by IP Australia

2018.Sep.19

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)